Proprietary TRPV6-targeting peptide platform enables highly targeted treatments for several solid tumor cancers
Our discovery of a toxin in the saliva of the venomous northern short-tailed shrew has led to the creation and continued development of a new class of targeted cancer treatments.
Partner with us
We are seeking development and commercialization partners for SOR-C13. We are also seeking partnerships / research collaborations for our peptide-drug conjugate platform.
We are a private oncology-focused company with multiple assets in clinical and preclinical development approaching near-term inflection points. Contact us to learn about current investment opportunities for accredited investors.